Samsung Biologics signs KRW 93.48 billion contract manufacturing deal with European drugmaker

Bitget2026/10/02 08:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Samsung Biologics signed a contract manufacturing deal valued at KRW 93.48 billion.
Agreement runs from Oct. 2, 2026 to Dec. 31, 2031.
Contract value equals USD 68,754,502 at an Oct. 2, 2026 USD/KRW rate of 1,359.60.
Counterparty described as a Europe-based pharmaceutical company.
Deal size equals 2.05% of 2025 consolidated revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261002800830), on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Samsung Biologics signs KRW 93.48 billion contract manufacturing deal with European drugmaker

You may also like

Crypto prices